Total raised
$8.9M
Last: Series A 2010-04
Stage
Series A
Founded
2005
Headcount
6
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
ProtAb Ltd is focused on the development of therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. The companys first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). ProtAb operates as a subsidiary of Hadasit Bio-Holdings Ltd (HBL). HBL is a publicly traded subsidiary of Hadasit Ltd, the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel.
Funding history · 2 rounds · $8.9M total
2010-04
Series A
$4.0M
Date unknown
Seed
$3.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
antibodiesinflammatory-diseasesbiotechnologydiabetespharmaceuticalstherapeuticsautoimmune-diseases